IntelGenx Corp.   Report issue

For profit Phase 2
Founded: Saint Laurent Canada (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2018
NCT03402503
First Marketed Drug
2023
rizatriptan (maxalt)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

IntelGenx Corp. | INTELGENX CORP

Active Ingredients

Marketed Drugs (1)

rizatriptan (maxalt) (2023)

Drugs in Phase 2 Trials (1)

montelukast (singulair) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1